The invention relates to novel proteins with BAFF dominant negative antagonist, receptor antagonist activity and agonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of BAFF or APRIL-related disorders.

 
Web www.patentalert.com

< Dedifferentiated, programmable stem cells of monocytic origin, and their production and use

> Human p51 genes and gene products thereof

> T cell regulatory genes and methods of use thereof
~ 00530